Hasil Pencarian - Tony Elliott

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity

    Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity oleh David Thomson, Sophie Merrick, Ric Swindell, Joanna Coote, Kay Kelly, Julie Stratford, James Wylie, Richard Cowan, Tony Elliott, John Logue, Ananya Choudhury, Jacqueline Livsey

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre

    Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre oleh Mark Stares, Vishwani Chauhan, Jigi Moudgil‐Joshi, Qiu G. Kong, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Edward Mains, Steve Leung, Alexander Laird, Stefan N. Symeonides

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis

    A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis oleh Amarnath Challapalli, Sylvia Pearson, Anita V. Mitra, Marc Coe, Alastair Thomson, Tony Elliott, Peter Kirkbride, Lisa Pickering, Hannah Kirk, Emily Foulstone, Heidi Evans, Alicia Bravo, Amit K. Bahl

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

    Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. oleh Vincenza Conteduca, Simon J Crabb, Robert J Jones, Orazio Caffo, Tony Elliott, Emanuela Scarpi, Paolo Fabbri, Lisa Derosa, Francesco Massari, Gianmauro Numico, Sunnya Zarif, Catherine Hanna, Francesca Maines, Helen Joyce, Cristian Lolli, Ugo De Giorgi

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

    Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, internatio... oleh Martin Boegemann, Sara Khaksar, Guillaume Bera, Alison Birtle, Catherine Dopchie, Louis-Marie Dourthe, Els Everaert, Martin Hatzinger, Dirko Hercher, Werner Hilgers, Geoffrey Matus, Laura Garcia Alvarez, Laurent Antoni, Martin Lukac, Geneviève Pissart, Paul Robinson, Tony Elliott

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: